Recently, there have been increasing studies regarding the role of the tumor microenvironment in the treatment efficacy of EGFR-TKIs, including the programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathways7. Here, EGFR is linked to neoplasm.